Cancer Statistics, 2021.
Reads0
Chats0
TLDR
In the United States, the cancer death rate has dropped continuously from its peak in 1991 through 2018, for a total decline of 31%, because of reductions in smoking and improvements in early detection and treatment as mentioned in this paper.Abstract:
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence. Incidence data (through 2017) were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data (through 2018) were collected by the National Center for Health Statistics. In 2021, 1,898,160 new cancer cases and 608,570 cancer deaths are projected to occur in the United States. After increasing for most of the 20th century, the cancer death rate has fallen continuously from its peak in 1991 through 2018, for a total decline of 31%, because of reductions in smoking and improvements in early detection and treatment. This translates to 3.2 million fewer cancer deaths than would have occurred if peak rates had persisted. Long-term declines in mortality for the 4 leading cancers have halted for prostate cancer and slowed for breast and colorectal cancers, but accelerated for lung cancer, which accounted for almost one-half of the total mortality decline from 2014 to 2018. The pace of the annual decline in lung cancer mortality doubled from 3.1% during 2009 through 2013 to 5.5% during 2014 through 2018 in men, from 1.8% to 4.4% in women, and from 2.4% to 5% overall. This trend coincides with steady declines in incidence (2.2%-2.3%) but rapid gains in survival specifically for nonsmall cell lung cancer (NSCLC). For example, NSCLC 2-year relative survival increased from 34% for persons diagnosed during 2009 through 2010 to 42% during 2015 through 2016, including absolute increases of 5% to 6% for every stage of diagnosis; survival for small cell lung cancer remained at 14% to 15%. Improved treatment accelerated progress against lung cancer and drove a record drop in overall cancer mortality, despite slowing momentum for other common cancers.read more
Citations
More filters
Journal ArticleDOI
Neoadjuvant Treatment Strategies in Resectable Pancreatic Cancer.
TL;DR: Neoadjuvant treatment is a logical option, as it may overcome some of the limitations of adjuvant therapy and has already shown some encouraging results as discussed by the authors, however, no study to date can be considered practice changing.
Journal ArticleDOI
Circular RNA circSNX6 promotes sunitinib resistance in renal cell carcinoma through the miR-1184/GPCPD1/ lysophosphatidic acid axis
Kang-Bo Huang,Yi-Hui Pan,Guan-Nan Shu,Hao-Hua Yao,Xi Liu,Mi Zhou,Jinhuan Wei,Zhenhua Chen,Jun Lu,Zihao Feng,Wei Chen,Hui Han,Zhousan Zheng,Junhang Luo,Jiaxing Zhang +14 more
TL;DR: The role of circular RNAs (circRNAs) in regulating sunitinib resistance of RCC is largely unknown as discussed by the authors, however, the role of circRNAs is not well understood.
Journal ArticleDOI
Transdermal Delivery of Chemotherapeutics: Strategies, Requirements, and Opportunities.
Rabin Neupane,Sai H.S. Boddu,Mariam Sami Abou-Dahech,Rinda Devi Bachu,David Terrero,R. Jayachandra Babu,Amit K. Tiwari +6 more
TL;DR: In this paper, the authors discuss the advantages of transdermal route over oral and parenteral routes for popular chemotherapeutic drugs and also discuss a possible in silico approach, Formulating for Efficacy™, to design trans-dermal formulations that would probably be economical, robust, and more efficacious.
Journal ArticleDOI
Adoptive NK Cell Therapy: A Promising Treatment Prospect for Metastatic Melanoma
TL;DR: In this article, the authors proposed a promising alternative approach for patients with treatment-resistant metastatic melanoma using adoptive cell therapy (ACT) for melanoma patients using Natural Killer (NK) cells, which achieved a favorable clinical safety profile with minimal toxicities.
Journal ArticleDOI
The role of microbiome in pancreatic cancer.
Jenny Jing Li,Mojun Zhu,Purna C. Kashyap,Nicholas Chia,Nguyen H Tran,Robert R. McWilliams,Tanios Bekaii-Saab,Wen Wee Ma +7 more
TL;DR: In this article, the human microbiome has been shown to modulate PDAC risk, contribute to tumorigenesis, impact the tumor microenvironment, and alter treatment response in pancreatic ductal adenocarcinoma (PDAC).
References
More filters
Journal ArticleDOI
Cancer statistics, 2019.
TL;DR: The overall cancer death rate dropped continuously from 1991 to 2016 by a total of 27%, translating into approximately 2,629,200 fewer cancer deaths than would have been expected if death rates had remained at their peak.
Journal ArticleDOI
Cancer statistics, 2016
TL;DR: Overall cancer incidence trends are stable in women, but declining by 3.1% per year in men, much of which is because of recent rapid declines in prostate cancer diagnoses, and brain cancer has surpassed leukemia as the leading cause of cancer death among children and adolescents.
Journal ArticleDOI
Reduced lung-cancer mortality with low-dose computed tomographic screening.
Denise R. Aberle,Amanda M. Adams,Christine D. Berg,William C. Black,Jonathan D. Clapp,Richard M. Fagerstrom,Ilana F. Gareen,Constantine Gatsonis,Pamela M. Marcus,JoRean D. Sicks +9 more
TL;DR: Screening with the use of low-dose CT reduces mortality from lung cancer, as compared with the radiography group, and the rate of death from any cause was reduced.
Journal ArticleDOI
Sex differences in immune responses
Sabra L. Klein,Katie L. Flanagan +1 more
TL;DR: It is emphasized that sex is a biological variable that should be considered in immunological studies and contribute to variations in the incidence of autoimmune diseases and malignancies, susceptibility to infectious diseases and responses to vaccines in males and females.
Journal ArticleDOI
Colorectal cancer statistics, 2020.
Rebecca L. Siegel,Kimberly D. Miller,Ann Goding Sauer,Stacey A. Fedewa,Lynn F. Butterly,Lynn F. Butterly,Joseph C. Anderson,Joseph C. Anderson,Andrea Cercek,Robert A. Smith,Ahmedin Jemal +10 more
TL;DR: Progress against CRC can be accelerated by increasing access to guideline‐recommended screening and high‐quality treatment, particularly among Alaska Natives, and elucidating causes for rising incidence in young and middle‐aged adults.